Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594

Eastern Cooperative Oncology Group (ECOG) Study E1594 compared paclitaxel and cisplatin with three newer chemotherapy doublets in the treatment of patients with advanced nonsmall cell lung carcinoma (NSCLC). The accrual of patients with an ECOG performance status (PS) of 2 was discontinued due to a perceived rate of unacceptable toxicity.

[1]  G. Scagliotti,et al.  A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Diane D. Liu,et al.  Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer , 2000 .

[3]  V. Lorusso,et al.  Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Dimopoulos,et al.  Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Stephens,et al.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome , 2000, British Journal of Cancer.

[6]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Lilenbaum,et al.  Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma , 2000, Cancer.

[8]  A. Gregor,et al.  Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Paclitaxel 175 mg/m2 plus carboplatin versus paclitaxel 225 mg/m2 plus carboplatin for advanced non small-cell lung cancer (NSCLC). , 2000, Clinical lung cancer.

[10]  E. Espinosa,et al.  Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin , 1999, Cancer.

[11]  M. Arning,et al.  A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy , 1999, Cancer.

[12]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[13]  M. Tonato,et al.  The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. , 1998, Seminars in oncology.

[14]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Jiroutek.  Prognostic factors in advanced non-small cell lung cancer: Analysis of Eastern Cooperative Oncology group trials from 1981-1992 , 1998 .

[16]  C. Belani,et al.  Chemotherapy for advanced non-small cell lung cancer: past, present, and future. , 1997, Seminars in oncology.

[17]  R. Stahel,et al.  Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[19]  F. Muggia,et al.  Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. , 1995, Seminars in oncology.

[20]  K. Kelly,et al.  A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. , 1995, Seminars in oncology.

[21]  G. Giaccone,et al.  Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. , 1995, Seminars in oncology.

[22]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Ettinger,et al.  Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. , 1995, Seminars in oncology.

[24]  F. Invernizzi,et al.  Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. , 1994, Chest.

[25]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Guidi,et al.  A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.